<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688922</url>
  </required_header>
  <id_info>
    <org_study_id>PRACTIC080703</org_study_id>
    <nct_id>NCT00688922</nct_id>
  </id_info>
  <brief_title>Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study</brief_title>
  <acronym>PRACTIC</acronym>
  <official_title>Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study That Evaluates the Effects of Pravastatin for Acute Myocardial Infarction With LDL-Cholesterol Levels of 70-129 mg/dl</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka Acute Coronary Insufficiency Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osaka Acute Coronary Insufficiency Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Study is to determine whether early treatment with pravastatin can reduce
      adverse cardiac events in patients with acute myocardial infarction and minimally to mildly
      elevated serum Low Density Lipoprotein -Cholesterol (LDL-C) levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators previously reported the beneficial effect of early use of low-dose
      pravastatin on major adverse cardiac events in patients with acute myocardial infarction and
      mild to moderate hypercholesterolemia in the OACIS-LIPID Study. The PRACTIC study is designed
      as the OACIS-LIPID II trial to determine whether early treatment with pravastatin can reduce
      adverse cardiac events in patients with acute myocardial infarction and minimally to mildly
      elevated serum Low Density Lipoprotein -Cholesterol (LDL-C) levels.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combination of death, non-fatal myocardial infarction, unstable angina, coronary revascularization (except anticipated revascularization before randomization), non-fatal stroke and re-hospitalization due to heart failure or other cardiac causes.</measure>
    <time_frame>20, 50 and 80% of the projected number of patients have been enrolled in the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Each component of the primary outcome measures.</measure>
    <time_frame>20, 50 and 80% of the projected number of patients have been enrolled in the study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. the presence of 2 of the following 3 criteria:

               1. a clinical history of central chest oppression, pain, or tightness lasting for
                  ≥30 minutes

               2. typical electrocardiographic changes (i.e., ST-segment elevation of &gt;0.1 mV in ≥1
                  limb or 2 precordial leads, ST-segment depression &gt;0.1 mV in ≥2 leads, abnormal Q
                  waves, or T-wave inversion in ≥2 leads)

               3. an increase in the serum creatine kinase levels to &gt;2 times the normal laboratory
                  value.

          2. the serum level of LDL-C is ≥70 and 130&gt; mg/dl in the first blood examination soon
             after admission

        Exclusion Criteria:

          1. concurrent therapy with any HMG-CoA reductase inhibitor

          2. previous history of the side effects associated with any HMG-CoA reductase inhibitor

          3. life-threatening arrhythmia

          4. severe chronic congestive heart failure

          5. hepatic dysfunction

          6. renal failure

          7. cerebrovascular disease

          8. poor controlled diabetes

          9. pregnancy, lactation

         10. age &lt;20 years

         11. disability of taking medicine or absence of a written informed consent

         12. Patients whom the doctors consider inappropriate by any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yasuhiko Sakata, MD/PhD</last_name>
    <phone>81-6-6879-6612</phone>
    <email>sakatayk@medone.med.osaka-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shinsuke Nanto, MD/PhD</last_name>
      <phone>81-6-6416-1221</phone>
    </contact>
    <investigator>
      <last_name>Shinnsuke Nanto, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Higashi-Osaka City General Hospital</name>
      <address>
        <city>Higashi-Osaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiyuki Kijima, MD/PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yoshiyuki Kijima, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kawachi General Hospital</name>
      <address>
        <city>Higashi-Osaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masayoshi Mishima, MD/PhD</last_name>
    </contact>
    <investigator>
      <last_name>Masayoshi Mishima, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka Minami Medical Center, National Hospital Organization</name>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatsuya Sasaki, MD/PhD</last_name>
    </contact>
    <investigator>
      <last_name>Tatsuya Sasaki, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka Rosai Hospital</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masami Nishino, MD/PhD</last_name>
    </contact>
    <investigator>
      <last_name>Masami Nishino, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasuhiko Sakata, MD/PhD</last_name>
      <phone>81-6-6879-6612</phone>
      <email>sakatayk@medone.med.osaka-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Yasuhiko Sakata, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masatake Fukunami, MD/PhD</last_name>
    </contact>
    <investigator>
      <last_name>Masatake Fukunami, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka Police Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasunori Ueda, MD/PhD</last_name>
      <phone>81-6-6771-6051</phone>
    </contact>
    <investigator>
      <last_name>Yasunori Ueda, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hiroshi Ito, MD/PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Motoo Date, MD/PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Hiroshi Ito, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Motoo Date, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>November 28, 2008</last_update_submitted>
  <last_update_submitted_qc>November 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2008</last_update_posted>
  <responsible_party>
    <name_title>Hiroshi Sato</name_title>
    <organization>Osaka University Graduate School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

